Compare CNX & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CNX | GPCR |
|---|---|---|
| Founded | 1860 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.3B |
| IPO Year | 1998 | 2023 |
| Metric | CNX | GPCR |
|---|---|---|
| Price | $41.90 | $63.17 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $35.78 | ★ $104.64 |
| AVG Volume (30 Days) | ★ 2.1M | 816.4K |
| Earning Date | 04-30-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 763.33 | N/A |
| EPS | ★ 3.98 | N/A |
| Revenue | ★ $2,239,134,000.00 | N/A |
| Revenue This Year | $0.03 | N/A |
| Revenue Next Year | $9.44 | N/A |
| P/E Ratio | $10.48 | ★ N/A |
| Revenue Growth | ★ 76.76 | N/A |
| 52 Week Low | $27.68 | $13.24 |
| 52 Week High | $43.12 | $94.90 |
| Indicator | CNX | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 63.15 | 34.34 |
| Support Level | $36.33 | $60.42 |
| Resistance Level | N/A | $72.00 |
| Average True Range (ATR) | 1.55 | 3.33 |
| MACD | 0.20 | -0.97 |
| Stochastic Oscillator | 80.64 | 21.98 |
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.